Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Intersect ENT stock

Own Intersect ENT stock in just a few minutes.


Fact checked

Intersect ENT, Inc is a medical devices business based in the US. Intersect ENT shares (XENT) are listed on the NASDAQ and all prices are listed in US Dollars. Intersect ENT employs 402 staff and has a trailing 12-month revenue of around USD$84.1 million.

How to buy shares in Intersect ENT

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Intersect ENT. Find the stock by name or ticker symbol: XENT. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Intersect ENT reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Intersect ENT, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Intersect ENT. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Intersect ENT share price

Use our graph to track the performance of XENT stocks over time.

Intersect ENT shares at a glance

Information last updated 2021-02-24.
52-week rangeUSD$5.97 - USD$26.98
50-day moving average USD$24.192
200-day moving average USD$20.2021
Wall St. target priceUSD$23
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.129

Buy Intersect ENT shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Intersect ENT stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Intersect ENT financials

Revenue TTM USD$84.1 million
Gross profit TTM USD$87.4 million
Return on assets TTM -20.89%
Return on equity TTM -62.5%
Profit margin -71.45%
Book value $2.487
Market capitalisation USD$802.9 million

TTM: trailing 12 months

Shorting Intersect ENT shares

There are currently 965,560 Intersect ENT shares held short by investors – that's known as Intersect ENT's "short interest". This figure is 12.7% down from 1.1 million last month.

There are a few different ways that this level of interest in shorting Intersect ENT shares can be evaluated.

Intersect ENT's "short interest ratio" (SIR)

Intersect ENT's "short interest ratio" (SIR) is the quantity of Intersect ENT shares currently shorted divided by the average quantity of Intersect ENT shares traded daily (recently around 232105.76923077). Intersect ENT's SIR currently stands at 4.16. In other words for every 100,000 Intersect ENT shares traded daily on the market, roughly 4160 shares are currently held short.

However Intersect ENT's short interest can also be evaluated against the total number of Intersect ENT shares, or, against the total number of tradable Intersect ENT shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Intersect ENT's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Intersect ENT shares in existence, roughly 30 shares are currently held short) or 0.0298% of the tradable shares (for every 100,000 tradable Intersect ENT shares, roughly 30 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Intersect ENT.

Find out more about how you can short Intersect ENT stock.

Intersect ENT share dividends

We're not expecting Intersect ENT to pay a dividend over the next 12 months.

Have Intersect ENT's shares ever split?

Intersect ENT's shares were split on a 1:4 basis on 11 July 2014. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Intersect ENT shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Intersect ENT shares which in turn could have impacted Intersect ENT's share price.

Intersect ENT share price volatility

Over the last 12 months, Intersect ENT's shares have ranged in value from as little as $5.97 up to $26.98. A popular way to gauge a stock's volatility is its "beta".

XENT.US volatility(beta: 1.63)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intersect ENT's is 1.6286. This would suggest that Intersect ENT's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Intersect ENT overview

Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site